![]() |
![]() |
J Acupunct Res > Volume 37(4); 2020 > Article |
|
#1 | Microneedle* |
#2 | Microneedling therapy system |
#3 | Percutaneous collagen induction |
#4 | #1 OR #2 OR #3 |
#5 | Alopecia |
#6 | Hair loss |
#7 | #5 OR #6 |
#8 | #4 AND #7 |
Author (nation, y) | Mouse species (sex/no.) | Intervention | Interval/no./needle depth (mm) | Evaluation index | Results |
---|---|---|---|---|---|
Kang (Korea, 2016) [9] | C57BL6 (male/unknown) |
1) CON 2) MXD 3) MTS 4) HRHDT + MTS |
2× wk/5–6× (unknown)/0.2 |
1) Hair growth and length 2) Hair density and diameter 2) RT-PCR 3) Western blotting 4) Histological changes of hair follicles 5) Weight of body and organs |
1–4) MXD > MTS + HRHDT > MTS > CON 5) No changes in all groups |
Ju (Korea, 2014) [8] | C57BL6 (male/unknown) |
1) CON 2) MXD 3) MTS 4) GLE + MTS |
2× wk/6×/0.2 |
1) Hair growth and length 2) Hair density and diameter 2) RT-PCR 3) Western blotting 4) Histological changes of hair follicles 5) Weight of body and organs |
1–4) MXD > MTS + HRHDT > MTS > CON 5) No changes in all groups |
Lee (Korea, 2014) [6] | C57BL6 (male/15) |
1) CON 2) MXD 3) MTS |
q1d/16×/unknown |
1) Histological changes of hair follicles 2) Hair density and diameter 3) Immunohistochemical staining: FGF, VEGF 4) RT-PCR: VEGFR-2, FGF-2, EGF |
1–3) MXD > MTS > CON 4) RT-PCR: MXD > MTS > CON (FGF-2), MTS > MXD > CON (VEGFR-2, EGF) |
Kim (Korea, 2016) [5] | C57BL6 (female/16) |
1) CON 2) MTS 10 cycles) 0.15, 0.25, 0.5, 1.0 mm −0.5 mm) 3, 6, 10, 13× |
5× wk/15×/10 cycles) 0.15, 0.25, 0.5, 1.0 |
1) Hair density and diameter 2) Hair growth 3) RT-PCR: Wnt3a, β-catenin, VEGF, Wnt10b 4) Immunohistochemistry: Wnt3α, β-catenin, VEGF, Wnt10β |
1–2) In the 10-cycle group, 0.25 and 0.5 mm were better. In the 0.5 mm group, 10 cycles were better. 3–4) All the indices increased in 0.5 mm and 10 cycles. |
CON, control; MXD, minoxidil; MTS, microneedle therapy system; HRHDT, Hwangyeonhaedoktang; wk, week; d, day; RT-PCR, Real time polymerase chain reaction; GLE, Ganoderma Lucidum extract; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; EGF, epidermal growth factor.
Author (nation, year) | Gender/no. (type of hair loss) | Study design | Intervention | Interval/no./needle depth (mm) | Evaluation index | Results |
---|---|---|---|---|---|---|
Yoo (Korea, 2010) [7] | Female/6, male/2 (AA) | Non-RCT |
Left: MAL + PDT Right: MAL + PDT + MTS |
q4wk/3×/5 |
1) Hair growth 2) Histopathologic changes |
1) No difference was found 2) No difference was found |
Giorgio (Italy, 2020) [10] | Female/24, male/17 (AA) | Non-RCT |
A: MTS (9) B: ALA + PDT (15) C: ALA + PDT + MTS (17) |
q3wk/6×/1 | 1) Hair growth | 1) No response to treatment in group A. No response: (B:4, C:1). Response more than 50%: (B: 7, C: 10) |
Starace (Italy, 2020) [11] | Female/29 (AGA), male/14 (AGA), female/7 (TE) | Non-RCT | Conventional treatment (topical MXD) + MTS | q4wk/3×1.5 |
1) Hair pull test 2) No. and diameter of the hairs |
1) Negative in all patients 2) Frontal density (36.64%), vertex density (35.10%). Frontal diameter (9.75%). Vertex diameter (9.08%) |
Jha (India, 2019) [12] | Male/93 (AGA) | Non-RCT |
A: MXD (31) B: MXD + PRP (31) C: MXD + PRP + MTS (31) |
q3wk/4×/unknown |
1) Hair pull test 2) Hair growth 3) Terminal-to-vellus hair ratio(T:V ratio) 4) Self-satisfaction |
1) Negative ratio: A(15), B(20), C(27) 2) Improved: A (10), B (17), C (26) 3) Mean variation of T:V ratio: A (1.00), B (1.19), C (1.78) 4) Very satisfied: A (10), B (16), C (24) |
Dhurat (India, 2015) [13] | Male/4 (AGA) | Non-RCT | Conventional treatment (oral finasteride + topical MXD) +MTS | q1wk or q2wk/15×/1.5 |
1) Hair growth (standardized 7-point evaluation scale) 2) Self-satisfaction |
1) Improved: Grade +2 to +3 2) 75% improvement in 3 patients and 50% improvement in 1 patient |
Kumar (India, 2018) [14] | Male/68 (AGA) | RCT |
A: MXD + MTS (34) B: MXD (34) |
q1wk or q2wk/8×/1.5 |
1) Hair count 2) Patient satisfaction (VAS) |
1) Mean increase: 12.82 ± 6.82 (A), 1.89 ± 8.94 (B) 2) Mean variation of VAS: 2.97 ± 1.28 (A), 1.21 ± 0.90 (B) |
Dhurat (India, 2013) [15] | Male/100 (AGA) | RCT |
A: MXD + MTS (50) B: MXD (50) |
q1wk/12×/1.5 |
1) Hair count 2) Investigator evaluation 3) Patient satisfaction |
1) Mean increase: 91.40 ± 49.27 (A), 22.2 ± 19.34 (B) 2) Improvement: +2 to +3 (A: 80%), 0 to +1 (B: 100%) 3) More than 50% improvement: (A: 82%), (B: 4.5%) |
Li (China, 2020) [17] | Male/90 (AGA) | RCT |
A: MXD + MTS (30) B: MTS (30) C: MXD (30) |
q2wk/48×/unknown |
1) Hair growth 2) Patient satisfaction |
1) More than moderate improvement: (A: 28), (B: 11), (C: 13) 2) More than 50% improvement: (A: 24), (B: 4), (C: 6) |
Liu (China, 2019) [16] | Male/90 (AGA) | RCT |
A: MXD + MTS (30) B: MXD (30) C: scalp nutrient solution (30) |
q1wk/20×/unknown |
1) Hair growth 2) Investigator evaluation 3) Patient satisfaction |
1) A was better than B and C (p < 0.05). B and C were equally effective. 2) Improved: (A: 26), (B: 25), (C: 26) 3) Improved: (A: 26), (B: 23), (C: 25) |
AA, alopecia areata; RCT, randomized controlled trials; MAL, methyl aminolevulinate; PDT, photodynamic therapy; MTS, microneedle therapy system; wk, week; ALA, 5-aminolevulinic acid; AGA, androgenetic alopecia; TE, telogen effluvium; MXD, minoxidil; MTS, microneedle therapy system; PRP, platelet rich plasma; VAS, visual analog scale.
![]() |
![]() |